Pfizer (NYSE:PFE) Reaches New 12-Month High – Still a Buy?

Pfizer Inc. (NYSE:PFE)’s stock price hit a new 52-week high on Tuesday. The company traded as high as $30.15 and last traded at $30.0580, with a volume of 4,905,624 shares traded. The stock had previously closed at $29.44.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer shares recently outperformed the broader market in a trading session, reflecting renewed investor interest in pharmaceutical stocks as technology shares weakened. The stock is also trading near its one-year high and above its 50-day and 200-day moving averages, indicating improved momentum. Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs
• Positive Sentiment: Investor confidence has been supported by Pfizer’s 2026 oncology progress, including breast-cancer approvals and a multibillion-dollar cancer alliance. Pfizer also generated a positive year-to-date total return, including dividends, reinforcing the case that its pipeline transition may be gaining credibility. What Pfizer Bulls Got Right
• Positive Sentiment: Pfizer’s approximately 5.8% dividend yield remains a central attraction for income investors. Its latest reported quarter also exceeded analyst expectations for earnings and revenue, while management’s fiscal 2026 earnings guidance provides a framework for valuation. What Have Pfizer Stock Holders Really Earned?
• Neutral Sentiment: Pfizer disclosed an ongoing study evaluating exposure to etrasimod in breastfeeding women. The update may support future labeling and commercial planning, but it does not provide efficacy or approval results that would immediately change the investment outlook. Pfizer’s Etrasimod Breastfeeding Study
• Negative Sentiment: Despite the dividend, Pfizer’s share-price performance over the past five years has lagged the S&P 500. That history, along with a relatively elevated earnings multiple and sharply lower recent net margins, may limit enthusiasm among growth-oriented investors. What Have Pfizer Stock Holders Really Earned?

Analyst Ratings Changes

A number of research firms have commented on PFE. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday, October 10th. Weiss Ratings upgraded shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, August 31st. HSBC increased their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock a “hold” rating in a research note on Thursday, September 10th. Scotiabank raised their price target on Pfizer from $30.00 to $33.00 and gave the stock an “outperform” rating in a report on Tuesday, October 6th. Finally, Guggenheim restated a “buy” rating on shares of Pfizer in a research report on Tuesday, October 13th. Five investment analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $28.72.

Pfizer Trading Down 0.8%

The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. The company has a fifty day moving average of $28.19 and a two-hundred day moving average of $26.59. The stock has a market capitalization of $170.28 billion, a price-to-earnings ratio of 39.31, a P/E/G ratio of 2.04 and a beta of 0.32.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. The firm had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. Pfizer’s quarterly revenue was up 2.6% on a year-over-year basis. During the same period last year, the firm posted $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 7th. Stockholders of record on Friday, November 6th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 6th. This represents a $1.72 annualized dividend and a dividend yield of 5.8%. Pfizer’s payout ratio is presently 226.32%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in PFE. Retirement Wealth Solutions LLC lifted its position in Pfizer by 144.6% in the third quarter. Retirement Wealth Solutions LLC now owns 861 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 509 shares during the period. Evolution Wealth Management Inc. boosted its holdings in Pfizer by 132.2% in the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 566 shares in the last quarter. Keb Asset Management LLC purchased a new stake in Pfizer in the 2nd quarter valued at approximately $26,000. Field & Main Bank acquired a new position in Pfizer during the 2nd quarter worth approximately $27,000. Finally, Global Trust Asset Management LLC increased its position in Pfizer by 126.7% during the 1st quarter. Global Trust Asset Management LLC now owns 1,163 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 650 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Company Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.